| May 1 |
ISTA Pharmaceuticals Announces New Phase III Clinical Findings to
Support Bepreve NDA Filing |
| May 1 |
Paloma Pharmaceuticals Presents at the Association for Research in
Vision and Ophthalmology Meeting |
| May 1 |
Lilly Oncology to Unveil More Than 50 Studies at ASCO 2008 |
| May 1 |
Coversyl Protects Hypertensive Patients Against New-onset Diabetes |
| May 1 |
New Study Raises Questions About Prostate Cancer Therapies
Targeting Insulin-Like Growth Factor Receptor |
| May 1 |
Resolvyx Compounds Show Promise In Treatment of Ocular Disease |
| May 1 |
Shire to Present Additional Scientific Data on ADHD Treatment
Portfolio at American Psychiatric Association Annual Meeting |
| May 2 |
BioLineRx Presents BL-1020 Phase 2a Data at Society of Biological
Psychiatry 63rd Annual Scientific Convention & Meeting |
| May 2 |
Celgene Cellular Therapeutics Announces Clinical Transplant of
Human Placenta-Derived Stem Cells |
| May 2 |
Increases in West Nile Virus Replikin Concentrations Precede
Increases in the Number of Human Cases |
| May 2 |
Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at
the American Psychiatric Association Annual Meeting |
| May 2 |
Somaxon Pharmaceuticals Announces Data to Be Presented at American
Psychiatric Association 161st Annual Meeting |
| May 2 |
IRX Therapeutics to Present Phase 2b Results at 3rd European
Conference on Head & Neck Oncology |
| May 2 |
Asphelia to Present At Digestive Disease Week 2008 in San Diego |
| May 2 |
Four Out of Five High Blood Pressure Related Deaths Occur in
Developing World |
| May 2 |
More Than a Quarter of Americans Experience Pain |
| May 5 |
BioDelivery Sciences Presenting Phase III Data on BEMA Fentanyl at
American Pain Society Meeting |
| May 5 |
Anti-HIV NanoViricide Drug Candidate Demonstrates Significant
Therapeutic Efficacy in Animal Trials |
| May 5 |
Anesiva Announces Publication of Phase 3 Zingo Data in the Journal
Pediatrics |
| May 5 |
QLT completes enrollment in the RADICAL study |
| May 5 |
YM Biosciences Announces Presentations for Aerolef at American Pain
Society Annual Meeting |
| May 5 |
Phase 3 Data Regarding Anti-RSV Antibody To Be Presented at
Pediatric Academic Societies (PAS) Annual Meeting |
| May 5 |
Results Published in JACC Show Clinical Advantage of Switching to
Angiomax from Heparin in Acute Coronary Syndrome Patients
Undergoing Early Invasive Treatment |
| May 5 |
N30 Pharma Announces Completion of Phase 1 Clinical Studies With
N30-201 |
| May 5 |
Senetek PLC Announces Positive Results from Pyratine-6(TM) Clinical
Trial in Patients with Acne Rosacea |
| May 5 |
Can-Fite Successfully Completed Phase I Clinical Trial with its 2nd
Drug CF102 |
| May 5 |
Efficacy of FluMist in Children Highlighted at Pediatric Academic
Societies Meeting |
| May 5 |
Study Shows Physician Judgment is Important in Reducing Rate of
RSV-Related Hospitalizations Among High-Risk Infants |
| May 5 |
A Safer Alternative to Aspirin? |
| May 5 |
Kidney Disease Substantially Worsens in a Fourth of African
Americans Despite Therapy for Hypertension |
| May 5 |
Unique Three-Year Data Demonstrating Long-Term Efficacy and Safety
of Raptiva in the Treatment of Psoriasis Published in the British
Journal of Dermatology |
| May 5 |
QRxPharma Releases Successful Phase 3 Study Results for 'Dual
Opioid' Pain Therapy |
| May 5 |
Divigel (estradiol gel) 0.1 Percent Offers Lowest Approved Dose of
Estradiol for Treatment of Moderate to Severe Hot Flashes
Associated with Menopause |
| May 5 |
Clinical Data Demonstrates 5-Year Efficacy and Safety of Aquamid in
Facial Augmentation |
| May 5 |
New Data on Seroquel XR in Treatment of Both Major Depressive
Disorder and Generalized Anxiety Disorder Presented at APA Annual
Meeting |
| May 6 |
Treprostinil Data to be Presented at Annual Meeting of the American
Thoracic Society |
| May 6 |
Affitech Announces Achievement of Significant Milestone in Antibody
Discovery Collaboration |
| May 6 |
NicOx announces U.S. phase 2a results for PF-03187207 and gives an
update on continuing NO-prostaglandin program |
| May 6 |
Novartis Menveo Vaccine Shows Superior Immune Response Against Four
Types of Meningitis Disease in Pivotal Phase III Trial |
| May 6 |
Two Year Study Confirms Supprelin LA Implant Maintains Profound
Suppression of Hormones in Children With Premature Onset Puberty |
| May 6 |
YM Biosciences Announces Schedule of Nimotuzumab Presentations at
ASCO 2008 Annual Meeting |
| May 6 |
New Data Show High Frequency of Medical Claims for Gastrointestinal
Events by Patients on Antiplatelet Therapy |
| May 6 |
New Study Confirms Dose-Accuracy of SoloSTAR Prefilled Insulin Pen |
| May 6 |
Early Study Results Show New Stem Cell Treatment Successfully
Treats Critical Limb Ischemia (CLI) Patients |
| May 6 |
Patients Treated with Risperidone Long-Acting Injection had a
Significantly Longer Time to Relapse Compared to Quetiapine in
International Clinical Study |
| May 6 |
Data Presented at the American Psychiatric Association (APA) Annual
Meeting Demonstrate Iloperidone's Efficacy and Safety, With Low
Rates of Movement and Metabolic Adverse Events |
| May 6 |
Clinical Data, Inc. Presents Vilazodone Data at 2008 Annual Meeting
of the APA |
| May 7 |
Treatment with Paliperidone ER May Be Associated with Significantly
Reduced Use of Mental Health Resources |
| May 7 |
LifeCycle Pharma Announces Positive Data from LCP-AtorFen Phase II
Clinical Program |
| May 7 |
Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin
Trial in Colorectal Cancer |
| May 7 |
ACE-011 Preclinical Data Published in the Proceedings of the
National Academy of Sciences |
| May 7 |
NKTR-118 Shows Substantial Oral Bioavailability and Extended
Half-Life in Phase 1 Clinical Data Presented at American Pain
Society Meeting |
| May 7 |
The Nation's Leading Plastic Surgeons Learn about ArteFill's Five
Year Safety and Long-Term Efficacy Data |
| May 7 |
Steroids Provide No Survival Benefit for Children With Bacterial
Meningitis |
| May 7 |
Seven Clinical Presentations on Tapentadol Immediate Release for
Acute Pain to Be Featured at 2008 American Pain Society Annual
Meeting |
| May 7 |
XTENT Announces Clinical Trial Data to be Presented at Annual
EuroPCR Meeting Next Week |
| May 7 |
Johnson & Johnson to Provide Webcast Presentation of Tapentadol
Phase 3 Clinical Data Presented at American Pain Society's Annual
Meeting |
| May 7 |
New data demonstrate that risperidone long-acting injection extends
time to relapse in patients with schizophrenia compared to those
treated with oral quetiapine |
| May 7 |
Abbott Scientists Present a New Approach for Treating
Attention-Deficit Hyperactivity Disorder |
| May 7 |
Preliminary Results from Phase 2 Genzyme Study Highlight Potential
of Novel Oral Compound for Gaucher Disease |
| May 7 |
New Analysis in Boys and Girls Shows the ADHD Patch, Daytrana
(methylphenidate transdermal system), Offered ADHD Symptom Control
for 12 Months |
| May 7 |
Shire's Investigational Nonstimulant ADHD Treatment Intuniv
(Guanfacine Extended Release) Demonstrated Significant Efficacy in
Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours
Postdose |
| May 7 |
Study Demonstrates Lexapro Significantly Improves Depression
Symptoms in Adolescents |
| May 7 |
iGuard.org Presents New Data on Statins at FDA Workshop
Demonstrating How Patient-Reported Information Can Enhance Drug
Safety Knowledge |
| May 7 |
Clinical Data on Somaxon Pharmaceuticals' Product Candidate for the
Treatment of Insomnia Presented at American Psychiatric Association
Annual Meeting |
| May 7 |
Savient Reports Favorable Interim Data from Puricase (pegloticase)
Open Label Extension Study |
| May 8 |
Discovery Labs Presents Surfaxin Data At Pediatric Academic
Societies Annual Meeting |
| May 8 |
KeyNeurotek Pharmaceuticals Reports Positive Phase I Data of Its
Cannabinoid Receptor-Agonist |
| May 8 |
Anacor to Present Clinical and Preclinical Data on Topical
Anti-Inflammatory Candidates, AN2728 and AN2898, at the
International Investigative Dermatology 2008 Conference |
| May 8 |
Array BioPharma Presents Additional Positive Phase 2 Results in
Inflammatory Pain Clinical Trial at the American Pain Society's
Annual Scientific Meeting |
| May 8 |
New Abbott Study of Investigational Vicodin CR Meets Primary
Efficacy Endpoints in Phase III Trial |
| May 8 |
New Lacosamide Data Provides Evidence for Long-Term Efficacy in
Diabetic Neuropathic Pain |
| May 8 |
Discovery Labs KL-4 Surfactant Technology Displays Antimicrobial
Properties and Does Not Induce Immune Response in Preclinical
Models |
| May 8 |
BEMA(TM) Fentanyl Phase III Data Demonstrating Efficacy and
Tolerability to be Presented at American Pain Society Annual
Meeting |
| May 8 |
GATTEX Abstracts Accepted for Presentation at DDW Conference; Phase
3 Short Bowel Syndrome Results Scheduled for Oral Plenary Session |
| May 8 |
Aethlon Medical Releases Smallpox Related Research Data |
| May 8 |
Data Show FLECTOR Patch Yields Significant Pain Reduction for Acute
Strains, Sprains and Contusions |
| May 8 |
Next Pharmaceuticals Announces a New Clinical Study Demonstrating
Relora Significantly Relieves Short-Term Anxiety in Healthy Women |
| May 8 |
Results of the Phase III Pivotal Study of Vyvanse (Lisdexamfetamine
Dimesylate) for the Treatment of ADHD in Adults Presented at
National Scientific Meeting of Psychiatrists |
| May 8 |
Collegium Pharmaceutical Inc. Presents Clinical Data for DETERx
Abuse-Deterrent Sustained Release Technology at American Pain
Society Meeting |
| May 8 |
Overview of Asenapine Data from Olympia Trial Program Presented at
American Psychiatric Association Annual Meeting |
| May 8 |
BioDelivery Sciences Presents Phase III BEMA Fentanyl Data |
| May 8 |
Alpharma Presents Data Addressing Abuse Liability Features, Safety
and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate
extended-release with sequestered naltrexone hydrochloride) at the
American Pain Society Annual Scientific Session |
| May 9 |
New Study Demonstrates Actemra (tocilizumab) Inhibits Progression
of Joint Damage in Rheumatoid Arthritis Patients |
| May 12 |
Nventa Announces Additional Positive Immunological Data From HspE7
Phase 1 Cervical Dysplasia Trial |
| May 12 |
Lunesta Study of Patients with Insomnia and Co-Morbid Generalized
Anxiety Disorder (GAD) Published in Archives of General Psychiatry |
| May 12 |
Affymax and Takeda Announce Long-Term Hematide Safety and
Effectiveness Data from Phase 2 Clinical Trials in Chronic Kidney
Disease Patients with Anemia |
| May 12 |
New Data From Phase 3 Study Suggests Tapentadol Immediate Release
Effective for Acute Pain From Common Foot Surgery |
| May 12 |
Starpharma Holdings Limited Reports Positive VivaGel Clinical Study
Results |
| May 12 |
Tengion to Present Preclinical Data For Regeneration of Entire
Bladder |
| May 12 |
Bone Medical further positive results from oral osteoporosis drug
trial |
| May 12 |
Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and
Offers Favorable Gastrointestinal Tolerability Profile |
| May 12 |
NovaBay's Lead Aganocide Compound, NVC-422, Well Tolerated in the
Bladder in Phase I Trial |
| May 12 |
Novelos Therapeutics Announces Positive Results in Ongoing Phase 2
Neoadjuvant Breast Cancer Trial at MUSC Hollings Cancer Center |
| May 12 |
Alseres Pharmaceuticals Announces 12 Month Interim Results from the
Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury |
| May 12 |
Repros Therapeutics Inc. Announces That Proellex Shows No Adverse
Cardiac Effects In A Pilot Trial |
| May 12 |
Nektar's PEGylation Technology Enables Peptide Mimetic, Highlighted
by Data Presented at 45th ERA-EDTA Congress |
| May 13 |
Ardana Announces a Preliminary Evaluation of Its Testosterone Cream
Pivotal Study and Provides an Update on Various Strategic Options |
| May 13 |
AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH
to be Published in European Urology Journal |
| May 13 |
Valeant Announces Successful Completion of Retigabine Phase III
Epilepsy Program Validating Novel Mechanism of Action |
| May 13 |
XIENCE V Drug Eluting Stent from Abbott Outperforms Market-Leading
Stent in Reducing Major Adverse Cardiac Events at Two Years |
| May 13 |
ENDEAVOR II Four-Year Results Demonstrate Long-Term Safety and
Durable Efficacy of Medtronic Drug-Eluting Stent |
| May 13 |
Gene Therapy Slows Progression of Fatal Neurodegenerative Disease
in Children |
| May 13 |
Peregrine Pharmaceuticals Reports Studies Published in 'Science'
Highlight Key Role of Phosphatidylserine (PS) in Viral Infections |
| May 13 |
SPIRIT III Results Reaffirm Strong Performance of Boston Scientific
PROMUS and TAXUS Express Stents |
| May 13 |
XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented
at EuroPCR Meeting |
| May 13 |
Novel Treatment Offers Insomnia Sufferers Hope of Quality Sleep |
| May 13 |
TAXUS Express Stent Shows Similarly Low Re-Intervention Rates in
Patients with Diabetes Compared to Non-Diabetics in ARRIVE Registry
Program |
| May 14 |
Kosan Announces Data Presentations at ASCO 2008 Annual Meeting |
| May 14 |
Significant Blood Pressure Reductions Seen in Difficult-to-Treat,
Black Patients Receiving Exforge-based Therapy |
| May 14 |
In a Phase II Study, Novartis Meningitis B Vaccine Has Potential to
Produce a Protective Immune Response in Infants, the Age Group Most
at Risk |
| May 14 |
Kosan Announces Data Presentations at ASCO 2008 Annual Meeting |
| May 14 |
Cervarix Shown to Provide Longest Duration of Sustained
Neutralizing Antibodies to Date |
| May 14 |
Lipid Sciences' Atherosclerosis Regression Data Presented at
EuroPCR 2008 Congress |
| May 14 |
New Data Shows 45 Percent of Patients with Stage 1 Hypertension
Reached Normotension with Benicar and Benicar HCT |
| May 14 |
PRoFESS Results Announced at XVII European Stroke Conference |
| May 14 |
Regenerative Medicine Offers Hope in Spinal Cord Injury |
| May 14 |
Regado Biosciences' REG1 Anticoagulation System Study Results
Published in the Journal of Thrombosis and Haemostasis |
| May 14 |
Ambrilia Biopharma Announces Positive Phase III Results -
Octreotide C2L |
| May 15 |
IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE)
Compassionate Access Program |
| May 15 |
Biopure Announces Publication of Phase II Proof-of-Concept Coronary
Trial |
| May 15 |
Allos Therapeutics Reports Interim Response and Safety Data from
Pivotal Phase 2 PROPEL Trial |
| May 15 |
Avelox Monotherapy Shows Strong Performance in Treating
Hospitalized Pneumonia Patients |
| May 15 |
Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119,
at Digestive Disease Week 2008 |
| May 15 |
New data show Tekturna HCT is twice as effective at reducing blood
pressure than the diuretic HCT alone |
| May 15 |
Adherex Announces Publication of ADH-1 Study in Cancer Research |
| May 15 |
Oculus Innovative Sciences to Participate in Third Congress of the
World Union of Wound Healing Societies in Toronto |
| May 15 |
New Hypertension Data Coming Out Of The American Society of
Hypertension Annual Meeting From Daiichi Sankyo |
| May 15 |
Cerenis Therapeutics Announces Successful Completion of Phase I
Clinical Trial of CER-002 for Treatment of Cardiovascular Disease |
| May 15 |
Tioga Pharmaceuticals to Present Asimadoline Phase 2b Data in
Irritable Bowel Syndrome at Digestive Disease Week 2008 Annual
Meeting |
| May 15 |
New Data on Bristol-Myers Squibb Oncology Compounds to Be Featured
in More Than 100 Abstracts at ASCO 2008 |
| May 15 |
CardioDynamics Announces Significant ICG Study with Nearly Three
Times the National Average Blood Pressure Control Rates at the
American Society for Hypertension Annual Scientific Meeting |
| May 15 |
Novel Microparticle Offers Immunological Breakthrough Against a
Range of Infectious Diseases and Potentially Some Cancers |
| May 15 |
Women Underestimate Their Risk of Spinal Fractures from
Osteoporosis, Reveals a Spine-health.com Study |
| May 15 |
Stable Stroke Patients More Likely to Die From a Nonstroke
Cardiovascular Event Than a Further Stroke |
| May 15 |
Independent Clinical Investigators to Present Data on Nymox BPH
Drug at American Urological Association Meeting in Chicago
September 25 |
| May 15 |
Depth of MedImmune's Respiratory Disease Research Program
Highlighted at Annual Meeting of the American Thoracic Society |
| May 15 |
International Endeavor Registry Reports Safety and Performance of
Medtronic Drug-Eluting Stent in Diverse Patient Population |
| May 15 |
Landmark ATHENA Study Findings With Multaq (dronedarone) Shows 24%
Reduction In Cardiovascular Hospitalization or Death in Patients
With Atrial Fibrillation |
| May 15 |
Azor Reduces Blood Pressure in Difficult to Treat Special
Populations |
| May 15 |
Forest Laboratories, Inc. and Laboratorios Almirall, S.A. to Host
Webcast to Discuss Aclidinium Bromide Data Presentations at the
American Thoracic Society Annual Congress |
| May 15 |
Researchers Report Thymosin B4 Promotes Spinal Cord Nerve Cell
Survival and Neurite Outgrowth |
| May 16 |
Dynavax TOLAMBA Chamber Study Misses Primary Endpoint; Company
Updates 2008 Financial Outlook |
| May 16 |
ADVENTRX Announces ANX-530 Safety Data From Registrational
Bioequivalence Clinical Study |
| May 16 |
Callisto Pharmaceuticals Reports Promising Interim Phase II Data
for Atiprimod in Advanced Carcinoid Cancer |
| May 16 |
75 Abstracts Evaluating Celgene Products to Be Presented at The
44th American Society of Clinical Oncology Meeting |
| May 16 |
Molecular Insight Pharmaceuticals, Inc. To Present Interim Phase 1
Data at ASCO on Azedra in Malignant Pheochromocytoma/Paraganglioma
Patients |
| May 16 |
Oncolytics Biotech Inc. Collaborators to Present Phase II Sarcoma
Trial Results at ASCO Annual Meeting |
| May 16 |
BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF
in Metastatic Melanoma at the 2008 American Society of Clinical
Oncology Meeting |
| May 16 |
Nexavar Significantly Improves Overall Survival by 47 Percent in
Asia-Pacific Liver Cancer Study |
| May 16 |
Pharmacopeia's First-in-Class Investigational Therapy PS433540
Achieves Statistically Significant Reductions in Blood Pressure in
Hypertensive Patients |
| May 16 |
Medarex Announces June 2nd Webcast Review and Discussion of
Ipilimumab Data Presented at ASCO |
| May 16 |
OncoGenex reports updated survival data on OGX-011 in a second-line
chemotherapy trial for patients with prostate cancer |
| May 16 |
The GI Company Reports Significant Reduction in Occurrence of Oral
Mucositis in Phase II Study; Abstract Posted Online at ASCO.org |
| May 16 |
GSK Announces Results of First Phase III Trial Evaluating
Tykerb/Tyverb (lapatinib) Plus Herceptin (trastuzumab) |
| May 16 |
ARIAD to Present Clinical Data at ASCO on the Anti-Tumor and Safety
Profile of Its Oral Investigational mTOR Inhibitor, Deforolimus |
| May 16 |
Genentech Provides Update on Studies of Investigational Biooncology
Agents to Be Presented at the American Society of Clinical Oncology
Meeting |
| May 16 |
New Data Highlighting the Potential Utility of ABRAXANE in
Combination with Targeted Therapies and Other Chemotherapeutic
Agents to Be Presented at ASCO |
| May 16 |
Nexavar Significantly Extends Overall Survival in Liver Cancer by
47 percent |
| May 16 |
Dynavax to Discuss TOLAMBA Chamber Data; Update 2008 Outlook in
Webcast This Morning |
| May 16 |
MolMed to present Phase II trial preliminary results for its
anticancer therapeutic Arenegyr at ASCO Annual Meeting 2008 |
| May 16 |
New Data Highlighting Possible Impact of ESA Reimbursement Policies
on Patient Care, Nation's Blood Supply, to be Presented at American
Society of Clinical Oncology (ASCO) Annual Meeting |
| May 16 |
Significant Anti-Tumor Activity of NKTR-102 in Patients With
Refractory Solid Tumors; Interim Data Published in ASCO 2008
Proceedings |
| May 16 |
Renhuang Pharmaceuticals, Inc. Co-Sponsors Sino-German Workshop on
Sleep Research |
| May 16 |
Seattle Genetics Announces Upcoming SGN-35 Presentation at the
American Society of Clinical Oncology Annual Meeting |
| May 16 |
Erbitux (cetuximab) Data Demonstrate Improvements in Response Rate
and Progression-Free Survival in Wild Type K-Ras Metastatic
Colorectal Cancer Patients in First-Line Setting |
| May 16 |
Significant Data on Erbitux (cetuximab) and ImClone Pipeline to Be
Presented at American Society of Clinical Oncology 2008 Annual
Meeting |
| May 16 |
Clinical Trial Data for Perforomist(TM) Inhalation Solution to be
Presented at ATS on May 20, 2008 |
| May 16 |
New Pfizer Data in Lung Cancer, Ewing's Sarcoma, Prostate Cancer
and Other Difficult-to-Treat Tumor Types to Be Presented at ASCO |
| May 16 |
Amgen Highlights Data to Be Presented at ASCO |
| May 16 |
Genentech Provides Update on Avastin Program |
| May 16 |
Bayer and Onyx Announce Nexavar Data Presentations at 44th American
Society of Clinical Oncology Annual Meeting |
| May 16 |
IDM Pharma Announces Presentations at 44th American Society of
Clinical Oncology Annual Meeting |
| May 16 |
Data from Pooled Analyses Demonstrates Welchol, Combined with
Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers
Blood Glucose in Adults with Type 2 Diabetes |
| May 16 |
CLSI Publishes Updated Reference Method for Broth Dilution
Antifungal Susceptibility Testing of Filamentous Fungi |
| May 16 |
Iressa Shows Promise For Treatment of Metastatic Breast Cancer When
Combined With Hormonal Therapy |
| May 16 |
Memory Pharmaceuticals Highlights Progress with Key Programs at its
R&D Day |
| May 16 |
New Drug Combination Brings One-Two Punch Against Acute Leukemia |
| May 16 |
New Data Support High Complete Remission Rates With Velcade
(Bortezomib) for Injection Based Therapies in Patients With Newly
Diagnosed Multiple Myeloma |
| May 19 |
NovaBay (NBY) Announces Positive Results From Phase IIA Study of
AgaNase For Nasal Decolonization of Staph including MRSA |
| May 19 |
Spectrum Pharmaceuticals to Present Phase 2 Data on Ortataxel in
Breast Cancer at the American Society of Clinical Oncology (ASCO)
Annual Meeting |
| May 19 |
NanoViricides' EKC Eye Drug Demonstrates Significant Therapeutic
Efficacy in Initial Animal Trials |
| May 19 |
RAD001 More Than Doubles Time Without Tumor Growth After Failure of
Standard Treatment in Patients with Advanced Kidney |
| May 19 |
Sangamo BioSciences Announces Presentation of Phase 1 Data of ZFP
Therapeutic at International Society for Cellular Therapy (ISCT)
Meeting |
| May 19 |
Phenomix Announces PHX1149 Phase 2b Clinical Trial Results for Type
2 Diabetes |
| May 19 |
Advair Reduces Exacerbations in COPD Patients With a History of
Exacerbations |
| May 19 |
Additional Digestive Disease Week Data Highlight Effects of Amitiza
in patients with IBS-C |
| May 19 |
RAD001 More Than Doubles Time Without Tumor Growth After Failure of
Standard Treatment in Patients with Advanced Kidney Cancer |
| May 19 |
Positive Clinical Data with Santarus' Zegerid Capsules in
Controlling 24-Hour Gastric Acidity Presented in DDW Abstract |
| May 19 |
Ikaria Completes Dosing of Phase 1a Clinical Study for IK-1001
(Sodium Sulfide) for Injection |
| May 19 |
Infant Vaccines Produce Autism Symptoms in New Primate Study by
University of Pittsburgh Scientists |
| May 19 |
TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data
Demonstrating Higher Overall Healing Versus Lansoprazole in
Patients with Erosive Esophagitis |
| May 19 |
Highest Replikin Concentrations and Cyclical Behavior Related to
Human Mortality Are Found in Malaria Trypanosomes |
| May 19 |
Adherex Announces ASCO Abstract of ADH-1 in Melanoma |
| May 19 |
Researchers Report Thymosin B4 Protects Human Cornea Epithelial
Cells Against Oxidative Damage |
| May 19 |
Pozen Announces PN 200 Podium Presentation at Digestive Disease
Week |
| May 19 |
Study Identifies Novel Glycan Markers, Anti-L & Anti-C, That
Predict Aggressive Crohn's Disease and Improve Differentiation
Between Crohn's Disease and Ulcerative Colitis |
| May 19 |
Argos Therapeutics Discusses Novel Solutions for Automated
Immunotherapy Manufacturing at ISCT Annual Meeting |
| May 19 |
Ark Makes Significant Advances with EG013 and EG014 Preclinical
Programmes |
| May 19 |
Pegasys/Copegus Show Benefit in Hard-to-Treat Latino Population
with Hepatitis C |
| May 19 |
Infant Primates Given Vaccines on U.S. Children's Immunization
Schedule Develop Biomedical and Behavioral Symptoms of Autism |
| May 19 |
ASCO Selects 28 Sarah Cannon Studies for Presentation at Annual
Meeting |
| May 19 |
ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent
Anti-Tumor Activity Without Toxicity in Metastatic Pancreatic
Cancer |
| May 19 |
RAD001 More Than Doubles Time Without Tumor Growth After Failure of
Standard Treatment in Patients With Advanced Kidney Cancer |
| May 19 |
Transgene Announces Promising Phase I Preliminary Results of Its
HCV Therapeutic Vaccine |
| May 19 |
ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent
Anti-Tumor Activity without Toxicity in Metastatic Pancreatic
Cancer |
| May 19 |
Phase 3 Gattex Results Presented at Annual Digestive Disease Week
Congress Highlight Potential New Treatment in Short Bowel Syndrome |
| May 19 |
VioQuest Pharmaceuticals Announces Upcoming Lenocta Oral
Presentation at the American Society of Clinical Oncology Annual
Meeting |
| May 19 |
Gloucester Pharmaceuticals Announces Positive Results from Phase 2b
Registration Trial of Romidepsin in Refractory CTCL |
| May 19 |
Amikacin Inhale Shows Promising Results in Phase II Study |
| May 20 |
Data Show Rufinamide, an Investigational Adjunctive Treatment for
Lennox- Gastaut Syndrome, Reduced Drop Attacks by More Than 40% |
| May 20 |
Compugen Presents Experimental Results for Three G-Protein Coupled
Receptor (GPCR) Ligands |
| May 20 |
KAI Pharmaceuticals Advances Third Product Candidate into Clinical
Studies |
| May 20 |
Halozyme Therapeutics Presents Pre-Clinical Studies on Dermal
Remodeling With HTI-501, a Lysosomal Proteinase |
| May 20 |
Protox to present BPH data at AUA Conference |
| May 20 |
ImmuPharma’s Cancer Drug Candidate IPP- 204106 Shows Complete
Response to Tumours in Multiple Human Cancer Cell Lines |
| May 20 |
Medication May Prevent Depression in Patients with Head and Neck
Cancer |
| May 20 |
Delayed Adverse Effects May Occur Following Injection with Cosmetic
Skin Fillers |
| May 20 |
Denosumab Osteoporosis Study Meets Primary and All Secondary Bone
Mineral Density Endpoints in Alendronate (FOSAMAX(R)) Transition
Study |
| May 20 |
Enzon Announces Clinical Data from PEG-SN38 and rhMBL Studies at
ASCO |
| May 20 |
Dynogen Presents Results of Its Positive Phase 2 IBS-d Study with
DDP225 |
| May 20 |
Ceragenix Announces Results of a Comparison Study of the Safety and
Efficacy of EpiCeram Cream for the Treatment of Mild to Moderate
Pediatric Atopic Dermatitis |
| May 20 |
Asthma Patients Not Adequately Controlled on ICS Alone More Likely
to Benefit From Advair Than Doubling the Dose of ICS |
| May 20 |
New Patient Satisfaction Study With budesonide/formoterol
Combination Therapy and fluticasone/salmeterol Combination Therapy
in Adults With Asthma |
| May 20 |
Concomitant Treatment With Nebulized Formoterol Fumarate and
Tiotropium Provides Clinically Significant Improvements for COPD
Patients |
| May 20 |
Elesclomol Study Shows Significant Improvement in Progression-Free
Survival for Chemotherapy-naïve Patients with Metastatic
Melanoma |
| May 20 |
Diasome Pharmaceuticals to Present at the 68th Annual American
Diabetes Association Meeting |
| May 20 |
Elesclomol Study Shows Significant Improvement in Progression-Free
Survival for Chemotherapy-Naive Patients With Metastatic Melanoma |
| May 20 |
Therapeutic DNA Vaccine Company Inovio Biomedical to Present at
Upcoming Scientific Conferences |
| May 20 |
Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium
Provides Significant Improvement in Dyspnea, COPD Symptoms and
Rescue Medication Use over Tiotropium Alone |
| May 20 |
Gilead Announces New Letairis (Ambrisentan) Data for the Treatment
of Patients With Pulmonary Arterial Hypertension (WHO Group 1) With
WHO Functional Class II or III Symptoms |
| May 20 |
Analysis of Ulcerative Colitis (UC) Time to Symptom Resolution Data
from Pivotal Study of Lialda (mesalamine) Presented at DDW |
| May 20 |
New Analysis Shows Efficacy of Remicade in Treatment of Ulcerative
Colitis in Patients with Recent Disease Onset or Long-Standing
Disease |
| May 20 |
Balsalazide 3.3 Grams Twice-Daily Shows Significant Improvement in
Bowel Function and Some Quality of Life Measures as Early as Week
Two |
| May 20 |
Dynogen Presents Results of Its Positive Phase 2a IBS-c Study with
DDP733 |
| May 20 |
Salix Presents New Rifaximin Phase IIb Data Demonstrating
Significant and Sustained Improvement in Diarrhea-Associated
Irritable Bowel Syndrome (D-IBS) |
| May 20 |
Ceftobiprole shows high cure rates in patients hospitalized with
community-acquired pneumonia |
| May 20 |
Forest and Almirall Announce Positive Results of Clinical Studies
for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for
the Treatment for COPD |
| May 20 |
Newly-Approved Cimzia Provides Rapid, Sustained Response in Crohn's
Patients |
| May 20 |
Study Analyzed Symbicort in Children with Persistent Asthma |
| May 21 |
Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8
agonist, D-3263, in Benign Prostatic Hyperplasia |
| May 21 |
Tioga Pharmaceuticals' Asimadoline Demonstrates Positive Results in
a Phase 2b Clinical Trial for the Treatment of Irritable Bowel
Syndrome |
| May 21 |
Indevus Presents Successful Phase III NEBIDO(R) Data at American
Urological Association |
| May 21 |
Ardea Biosciences Presents Preclinical Data on RDEA119
Demonstrating Favorable Anti-Inflammatory Profile for Potential Use
in Ulcerative Colitis |
| May 21 |
Data from Phase IIb trial of Elocalcitol in BPH presented at the
annual meeting of the American Urological Association |
| May 21 |
Ironwood Pharmaceuticals and Forest Laboratories Announce
Presentation of Linaclotide Phase 2b Chronic Constipation Study
Results |
| May 21 |
Genta Clinical Programs Featured in Multiple Abstracts at the
Annual Meeting of the American Society of Clinical Oncology |
| May 21 |
Medarex Reports Phase 1 Clinical Data of MDX-1100 at Digestive
Disease Week |
| May 21 |
Cell Genesys Reports Encouraging Interim Data From Phase 1 Clinical
Trial of CG0070 in Recurrent Bladder Cancer |
| May 21 |
Excellent clinical trial data from Photocure's photodynamic
diagnostic Lumacan |
| May 21 |
Alnylam and Collaborators Publish In Vivo Research on Validation of
a Mammalian Host Gene Involved in Malaria Infection and on the
Anti-Parasitic Efficacy of RNAi Therapeutics |
| May 21 |
Jennerex Publishes Promising Results from Cancer Clinical Trial of
JX-594 in Lancet Oncology |
| May 21 |
Schering-Plough To Initiate Phase III Studies With HCV Protease
Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients
and Those Who Failed Prior Treatment |
| May 21 |
PTC Therapeutics Announces Data Supporting Cough Frequency as a New
Outcome Measure in Evaluating Treatments for Cystic Fibrosis |
| May 21 |
Safety and Efficacy Results Presented From Largest Prospective
Controlled Clinical Study of Ulcerative Colitis |
| May 21 |
Sahajanand Medical Technologies PAINT Trial Results Support Safety
and Efficacy of the Infinnium and Supralimus Stents |
| May 21 |
ATHENA Clinical Results for Dronedarone (Multaq) Highlighted at the
World Cardiology Congress |
| May 21 |
QuatRx Pharmaceuticals Announces Presentation of Further Data from
Ophena (Ospemifene) Phase 3 Study for Treatment of Symptoms of
Vulvovaginal Atrophy |
| May 21 |
Watson Announces Positive Data for Its New Investigational Products
for Benign Prostatic Hyperplasia and Overactive Bladder |
| May 21 |
ImmunoCellular Therapeutics Announces Completion of
Proof-of-Principle Studies Demonstrating Efficacy of Cancer Stem
Cell Vaccine in Preclinical Model |
| May 21 |
Alba Therapeutics Announces the Presentation of Results of a Phase
IIa Clinical Trial for Larazotide Acetate for the Treatment of
Celiac Disease at the Digestive Disease Week Conference |
| May 21 |
Sanofi-aventis and Regeneron Update Aflibercept (VEGF Trap)
Clinical Development Program in Oncology |
| May 21 |
Abbott Presents Long-Term Data From Extension Study Showing Adult
Crohn's Patients Treated With Humira (Adalimumab) Maintained
Remission |
| May 21 |
Three-Year COPD Study Found No Increase in Cardiac Events With
Advair 500/50 |
| May 21 |
Plexxikon Announces Preclinical Data Demonstrating Dramatic
Improvement in Key Symptoms of Polycystic Kidney Disease |
| May 22 |
Wyeth and Progenics Announce Preliminary Clinical Trial Results for
Relistor Oral and Intravenous Formulations |
| May 22 |
AVANT Immunotherapeutics Announces Oral Presentation of CDX-110 at
ASCO Annual Meeting |
| May 22 |
Treprostinil Data Presented at American Thoracic Society Conference
Demonstrates Significant Clinical Progress in All Four Routes of
Administration |
| May 22 |
New Analysis Showed That High Dose Lipitor Can Reduce the Risk of
Cardiovascular Events in Bypass Surgery Patients |
| May 22 |
Ardea Announces Progress with HIV Non-Nucleoside Reverse
Transcriptase Inhibitor Program |
| May 22 |
Cougar Biotechnology to Present Clinical Data on CB7630
(Abiraterone Acetate) at American Society of Clinical Oncology 2008
Annual Meeting |
| May 22 |
Caphosol Relieves Oral Mucositis (OM) and Improves Quality-of-Life
in Cancer Patients Receiving Chemoradiation |
| May 22 |
Opexa Therapeutics Presents Myelin Reactive T-Cell Research at the
International Society of Cell Therapy Annual Meeting |
| May 22 |
Results Published in New England Journal of Medicine Show Angiomax
Improved Net Clinical Outcomes and Resulted in Improved Survival
Rates in the Most Severe Heart Attack Patients |
| May 22 |
QRxPharma Releases Additional Phase 3 Data for Q8003IR 'Dual
Opioid' Pain Therapy |
| May 22 |
Stabilizing Cancer-Fighting p53 Can Also Shield a
Metastasis-Promoter |
| May 22 |
Nearly 60 New Studies of Oral Xeloda (capecitabine) Featured at the
44th American Society of Clinical Oncology Annual Meeting |
| May 22 |
Anti-rejection Drug May Increase Risk of Diabetes After Kidney
Transplant |
| May 22 |
Rexin-G Monotherapy Reveals Significant Biological Activity without
Toxicity in Chemo-Resistant Metastatic Breast Cancer |
| May 22 |
Tioga Pharmaceuticals’ Asimadoline Demonstrates Positive
Results in a Phase 2b Clinical Trial for the Treatment of Irritable
Bowel Syndrome |
| May 22 |
Micromet to Present Clinical Update for BiTE Antibody
MT103/MEDI-538 at the International Conference on Malignant
Lymphomas |
| May 27 |
Favrille Announces Results from Phase 3 Registration Trial of
Specifid in Patients with Follicular B-Cell Non-Hodgkin's Lymphoma |
| May 27 |
Osteologix Presents Phase 2 Osteoporosis Data at a Major European
Medical Conference |
| May 27 |
Isotechnika reports final results of the PROMISE trial |
| May 27 |
ImmunoGen, Inc. Announces Presentations at Upcoming 2008 American
Society of Clinical Oncology Annual Meeting |
| May 27 |
Odanacatib, Merck's Investigational Cathepsin K Inhibitor, Reduced
Markers of Bone Turnover in Women with Breast Cancer and Bone
Metastases |
| May 27 |
AVANIR Announces Positive Outcome of Zenvia PK Study |
| May 27 |
Neose Announces Two Abstracts on GlycoPEGylated Factor VIIa
Accepted for Presentation at the Hemophilia 2008 World Congress |
| May 27 |
ThromboGenics Presents Further Results of the Vitreomacular
Traction Trial (MIVI IIT) at the Euretina Annual Meeting in Vienna |
| May 27 |
Cell Therapeutics, Inc. (CTI) Announces Presentations at American
Society of Clinical Oncology (ASCO) Annual Meeting |
| May 27 |
BMJ: Oral HRT More Than Doubles the Risk of Blood Clots |
| May 27 |
OSI Pharmaceuticals to Provide a Summary of Data Presented at the
2008 American Society of Clinical Oncology Meeting |
| May 27 |
Node-negative early stage breast cancer patients benefit from
Taxotere-based chemotherapy |
| May 27 |
Brainstorm Cell Therapeutics Chief Scientist, Dr. Daniel Offen, To
Present Results from New Parkinson's Study at International Stem
Cell Meeting in Tel Aviv |
| May 27 |
Node-Negative Early Stage Breast Cancer Patients Benefit from
Taxotere-Based Chemotherapy |
| May 27 |
Innate Pharma Announces Phase Iia Results with IPH 1101 as Second
Line Monotherapy in Metastatic Renal Cell Carcinoma |
| May 27 |
Synairgen present data regarding barrier function-improving peptide
at ATS |
| May 27 |
TARGETED GENE DELIVERY SIGNALS CANCER VACCINATION IN VIVO:
Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce
Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes in
Cancerous Lesions (ASCO 2008) |
| May 27 |
Global Study Reveals Differences in Standard of Care for
Osteoporosis Across the World |
| May 27 |
Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce
Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes in
Cancerous Lesions |
| May 28 |
NanoViricides in Discussions with Pharma about EKC Eye Drug
Candidate |
| May 28 |
Human Genome Sciences Reports Progress With Late-Stage Products and
New Initiatives |
| May 28 |
Study Showed Alimta (pemetrexed for injection) Improved Survival in
Certain Types of Non-Small Cell Lung Cancer |
| May 28 |
Elixir Pharmaceuticals Researchers Publish New Data Validating
Ghrelin as a Key Metabolic Regulator |
| May 28 |
Amgen Announces Webcast to Discuss Results of Denosumab Phase 3
Head-to-Head Study Versus Alendronate at the Upcoming European
Symposium on Calcified Tissues Conference |
| May 28 |
Sunesis Pharmaceuticals to Present Interim Clinical Data From
Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO
Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA
Congress |
| May 28 |
Santhera Presents Efficacy Data of SNT-317 in Congenital Muscular
Dystrophy at International Congress of Myology |
| May 28 |
Oculus Innovative Sciences Announces Publication of Microcyn
Technology Post-Caesarean Section Wound Study in Indian Medical
Gazette |
| May 28 |
Phase III Clinical Study Using BSD Medical's Systems for Treating
Pancreatic Cancer to Be Announced at ASCO |
| May 28 |
GPC Biotech Announces Data from Several Satraplatin Clinical Trials
to be Presented at ASCO Annual Meeting |
| May 28 |
Denosumab Achieved Superior Bone Mineral Density Gains in
Head-to-Head Trial versus Weekly Alendronate (Fosamax) |
| May 28 |
Astex Drug Candidates to be Presented at the 2008 American Society
of Clinical Oncology Annual Meeting |
| May 28 |
Advexin Improves Survival in Recurrent, Refractory Head and Neck
Cancer Patients |
| May 28 |
ImmunoCellular Therapeutics Announces Ability to Characterize
Distinct Antigens Between Cancers Using Monoclonal Antibody
Technology |
| May 28 |
Access Pharmaceuticals Presents New Data on the Company's Cobalamin
Technology at an International Polymer Therapeutics Symposium |
| May 28 |
Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and
Clinical Update on ProLindac Development at Prestigious
International Symposium |
| May 28 |
Nymox Reports Significant Long-Term Improvement in BPH Symptoms
After NX-1207 Treatment in New Multi-Center U.S. Study |
| May 28 |
Gene Therapy Increases Survival for End-Stage Head and Neck Cancer |
| May 29 |
Reduction of Pain, Itching, and Rash Shown in Study of Oncology
Patients by MPM Medical, Inc., Subsidiary of RBC Life Sciences |
| May 29 |
Novadaq Updates on Optix Data Reported at Euroretina |
| May 29 |
Repros Therapeutics Inc. Announces That Initial Findings for
Proellex Show No Adverse Effects on the Endometrium after One Year
on Drug |
| May 29 |
EpiCept Announces Presentation of EPC2407 Data at 2008 American
Society of Clinical Oncology Annual Meeting |
| May 29 |
Alfacell Corporation Announces Preliminary Results From Onconase
Phase IIIb Clinical Trial |
| May 29 |
BrainStorm Cell Therapeutics NTF Cells Shows Significant Advantage
in Pre-Clinical Study for Parkinson's Disease |
| May 29 |
Arenegyr: Key Preliminary Results of Phase II Trials in
Mesothelioma and Colorectal Cancer Presented at ASCO |
| May 29 |
Long-Term Followup in Phase 3 CLL Trial Shows Genasense is
Associated with Significantly Increased Survival in All Responders |
| May 29 |
Strativa Pharmaceuticals Announces Preliminary Results from
Onconase Phase IIIb Clinical Trial |
| May 29 |
EpiCept Announces Presentation of EPC2407 Data at 2008 American
Society of Clinical Oncology Annual Meeting |
| May 29 |
GenVec Presents Encouraging Data on TNFerade in Esophageal Cancer |
| May 29 |
New England Journal of Medicine Publishes Results From a Relistor
Phase 3 Clinical Study |
| May 29 |
Data from Pivotal Phase III Studies of Gilead's Letairis
(ambrisentan) for Pulmonary Arterial Hypertension (WHO Group 1) in
Patients with WHO Functional Class II or III Symptoms Published in
Circulation |
| May 29 |
Cleviprex(TM) Reduces and Controls Acutely Elevated Blood Pressure
in Elderly Patients, According to New Analysis from VELOCITY Trial |
| May 29 |
Introgen Presents Top Line Data from Phase III Advexin Clinical
Trial |
| May 29 |
Salix Presents New Rifaximin Phase IIb Data Demonstrating
Significant And Sustained Improvement in Diarrhea-Associated
Irritable Bowel Syndrome (d-IBS) |
| May 29 |
Cellceutix Cancer Compound: Crunching the Numbers |
| May 29 |
Advexin Improves Survival in Recurrent, Refractory Head and Neck
Cancer Patients |
| May 29 |
Intravenous Infusions of REXIN-G - Demonstrates Dose-Dependent
Anti-Tumor Activity Without Toxicity in Patients |
| May 29 |
LifeCycle Pharma to Present Data at American Transplant Congress
(ATC) in Toronto |
| May 29 |
Graceway Pharmaceuticals Reports Study in Journal of Pediatrics:
Atoplclair is Effective Monotherapy for Mild to Moderate Atopic
Dermatitis in Infants and Children |
| May 29 |
Phase I/II Study of Targeted Gene Delivery In Vivo - Intravenous
Infusions of REXIN-G - Demonstrates Dose-Dependent Anti-Tumor
Activity Without Toxicity in Patients With Progressive
Chemo-Resistant Bone and Soft Tissue Sarcoma (ASCO 2008) |
